Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant decline in short interest in the month of May. As of May 15th, there was short interest totalling 369,100 shares, a decline of 64.2% from the April 30th total of 1,030,000 shares. Based on an average daily trading volume, of 822,600 shares, the days-to-cover ratio […]
Elevation Oncology (NASDAQ:ELEV – Get Rating) and Freeline Therapeutics (NASDAQ:FRLN – Get Rating) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their profitability, earnings, valuation, institutional ownership, analyst recommendations, dividends and risk. Institutional & Insider Ownership 68.0% of Elevation Oncology shares […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) – Investment analysts at Wedbush lifted their Q2 2023 earnings per share estimates for Elevation Oncology in a research note issued on Monday, May 15th. Wedbush analyst R. Driscoll now expects that the company will earn ($0.25) per share for the quarter, up from their prior estimate of […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) was the recipient of a large growth in short interest in the month of April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 688.7% from the April 15th total of 130,600 shares. Based on an average daily trading volume, of 766,300 shares, […]
Elevation Oncology, Inc. (NASDAQ:ELEV – Get Rating) saw a significant growth in short interest in April. As of April 30th, there was short interest totalling 1,030,000 shares, a growth of 688.7% from the April 15th total of 130,600 shares. Based on an average daily volume of 766,300 shares, the short-interest ratio is presently 1.3 days. […]